We provide ongoing medical supervision, individualized dose adjustments, and evidence-based lifestyle guidance to help you achieve your weight loss goals safely and effectively
Mean weight reductions in SURMOUNT-1 reached 15%, 19.5%, and 20.9% for the three tirzepatide doses, compared to 3.1% with placebo
Athletes who want to relieve muscle pain and increase athletic performance Those who want to increase their cognitive performance (memory, attention, learning ability)
Published clinical research has characterised the compound in controlled trials: a Phase 2 obesity trial reported dose-dependent body-weight change in the study population (Jastreboff et al., 2023), and a separate Phase 2 trial investigated the GIP/GLP-1/glucagon agonist in people with type 2 diabetes (Rosenstock et al., 2023)
doi: 10.1038/s41598-018-23408-0 27 HadianKStockwellBR